| Methods |
Minimum 7‐day washout; 4‐week single‐blind placebo run‐in; inclusion criteria= supine DBP 100‐114 mm Hg during final 2 weeks of run‐in, mean supine DBP could not vary by more than 7 mm Hg between weeks 2 and 3 or weeks 3 and 4 of run‐in or by more than 10 mm Hg between weeks 2 and 4 of run‐in; 4‐week double‐blind treatment |
| Participants |
Telmisartan 40 mg: n=40(23 males,17 females); mean age=54.3 years; baseline supine SBP=154.6 mm Hg, DBP=102.4 mm Hg, HR=71.8 bpm;
Telmisartan 80 mg: n=41(26 males,15 females); mean age=50.6 years; baseline supine SBP=154.2 mm Hg, DBP=103.1 mm Hg, HR=72.0 bpm;
Telmisartan 120 mg: n=41(25 males,16 females); mean age=52.0 years; baseline supine SBP=153.9 mm Hg, DBP=102.0 mm Hg, HR=72.0 bpm;
Placebo: n=43(24 males,19 females); mean age=52.0 years; baseline supine SBP=159.5 mm Hg, DBP=104.9 mm Hg, HR=72.5 bpm |
| Interventions |
Telmisartan 40 mg once daily;
Telmisartan 80 mg once daily;
Telmisartan 120 mg once daily;
Placebo;
taken with water (120 ml) between 6 AM and 9 AM and at least 1 h before breakfast |
| Outcomes |
Mean change from baseline in trough standing SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in trough standing HR;
Mean change from baseline in trough supine HR;
WDAE |
| Notes |
BP change and SE of change reported; endpoint BP and SD not reported; calculated SD of change from N and SE of change; change in BP data from Table II, p. 1385; Jadad score=4; funding source= Boehringer Ingelheim Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
